Back

TET1 and TDG suppress intestinal tumorigenesis by down regulating the inflammatory and immune response pathways

Tricarico, R.; Madzo, J.; Scher, G.; Maegawa, S.; Jelinek, J.; Scher, C.; Chang, W.-C.; Nicolas, E.; Zhou, Y.; Slifker, M.; Devarajan, K.; Cai, K. Q.; Nakajima, P.; Xu, J.; Mancuso, P.; Doneddu, V.; Bagella, L. M.; Ingram, J.; Balachandran, S.; Peshkova, I.; Koltsova, E.; Grivennikov, S.; Yen, T. J.; Issa, J.-P.; Bellacosa, A.

2019-06-21 cancer biology
10.1101/676445 bioRxiv
Show abstract

IntroductionAberrant DNA methylation is frequently observed in colorectal cancer (CRC), but the underlying mechanisms are poorly understood. Ten-Eleven Translocation (TET) dioxygenases and DNA repair enzyme Thymine DNA Glycosylase (TDG) are involved in active DNA demethylation by generating and removing, respectively, novel oxidized cytosine species. Mutations of TET1 and TDG, and alterations of the levels of oxidized cytosine species have been identified in human CRC cases, but the biological significance of the TET-TDG demethylation axis in intestinal tumorigenesis is unclear.\n\nMaterial and MethodsWe generated ApcMin mice with additional inactivation of Tet1 and/or Tdg, and characterized the methylome and transcriptome of intestinal adenomas by DREAM and RNA sequencing, respectively.\n\nResultsTet1- and/or Tdg-deficient ApcMin mice show enhanced intestinal tumorigenesis in comparison to wild type Tet1 and Tdg ApcMin mice. Specifically, Tet1 and/or Tdg-deficient ApcMin adenomas manifested increased size or features of erosion and stroma activation. Methylome analysis revealed progressive loss of global DNA hypomethylation in colonic adenomas from Tet1- and Tdg-deficient ApcMin mice, and hypermethylation of CpG islands in Tet1-deficient ApcMin mice. In addition, RNA sequencing showed upregulation of genes in inflammatory and immune response pathways in Tet1-and Tdg-mutant colonic adenomas compared to control ApcMin adenomas.\n\nConclusionsTaken together, these findings demonstrate the important role of active DNA demethylation mediated by TET-TDG in reducing intestinal tumor formation, by modulating the epigenome and inflammatory/immune responses. This study highlights a novel mechanism of epigenetic deregulation during intestinal tumorigenesis with diagnostic, therapeutic and prognostic implications.

Matching journals

The top 1 journal accounts for 50% of the predicted probability mass.

1
Clinical Epigenetics
53 papers in training set
Top 0.1%
50.4%
50% of probability mass above
2
International Journal of Cancer
42 papers in training set
Top 0.3%
3.5%
3
Epigenetics
43 papers in training set
Top 0.2%
3.5%
4
Gastroenterology
40 papers in training set
Top 0.6%
3.5%
5
Cellular and Molecular Gastroenterology and Hepatology
41 papers in training set
Top 0.2%
3.5%
6
Cancers
200 papers in training set
Top 2%
2.8%
7
Scientific Reports
3102 papers in training set
Top 60%
1.6%
8
Cancer Epidemiology, Biomarkers & Prevention
17 papers in training set
Top 0.3%
1.6%
9
npj Precision Oncology
48 papers in training set
Top 0.6%
1.6%
10
Gut
36 papers in training set
Top 0.5%
1.6%
11
British Journal of Cancer
42 papers in training set
Top 1.0%
1.4%
12
Epigenomics
10 papers in training set
Top 0.1%
1.4%
13
BMC Cancer
52 papers in training set
Top 2%
1.3%
14
Cancer Medicine
24 papers in training set
Top 1%
1.2%
15
Molecular Oncology
50 papers in training set
Top 0.6%
1.2%
16
PLOS ONE
4510 papers in training set
Top 63%
0.9%
17
Clinical and Translational Medicine
30 papers in training set
Top 0.8%
0.9%
18
Journal of Clinical Medicine
91 papers in training set
Top 6%
0.8%
19
Frontiers in Pharmacology
100 papers in training set
Top 4%
0.8%
20
European Journal of Cancer
10 papers in training set
Top 0.6%
0.7%
21
JNCI: Journal of the National Cancer Institute
16 papers in training set
Top 0.7%
0.7%
22
Biology Open
130 papers in training set
Top 3%
0.7%
23
Microbiome
139 papers in training set
Top 3%
0.7%
24
The Journal of Molecular Diagnostics
36 papers in training set
Top 0.5%
0.7%
25
Frontiers in Oncology
95 papers in training set
Top 4%
0.6%